AbstractDespite advances in hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies, relapse remains the leading cause of death after transplant. Biologic and clinical investigations are needed to combat this primary cause of death after transplantation. The National Cancer Institute held international workshops in 2009 and 2012 to help address this problem. Three major initiatives for coordinated research were proposed: 1) To establish multicenter networks for basic, translational, epidemiologic and clinical research; 2) To establish a network of biorepositories for the collection of samples before and after HSCT to aid in laboratory and clinical studies; and 3) To refine, implement and study proposed d...
Significant progress has been made over the past decade in haploidentical transplantation, with the ...
Disease relapse remains a major cause of mortality following allogeneic hematopoietic cell transplan...
AbstractOutcomes of hematopoietic cell transplantation continue to improve. New techniques have redu...
AbstractDespite advances in hematopoietic stem cell transplantation (HSCT) for the treatment of hema...
The National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatme...
AbstractIn the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment...
AbstractIn the Second Annual National Cancer Institute’s Workshop on the Biology, Prevention, and Tr...
The National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatme...
AbstractIn the National Cancer Institute's Second International Workshop on the Biology, Prevention,...
Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantati...
AbstractIn the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment...
Prevention of relapse after allogeneic hematopoietic stem cell transplantation is the most likely ap...
The success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the infusion of ...
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for treatme...
Relapse has become the major cause of treatment failure after allogeneic hematopoietic stem cell tra...
Significant progress has been made over the past decade in haploidentical transplantation, with the ...
Disease relapse remains a major cause of mortality following allogeneic hematopoietic cell transplan...
AbstractOutcomes of hematopoietic cell transplantation continue to improve. New techniques have redu...
AbstractDespite advances in hematopoietic stem cell transplantation (HSCT) for the treatment of hema...
The National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatme...
AbstractIn the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment...
AbstractIn the Second Annual National Cancer Institute’s Workshop on the Biology, Prevention, and Tr...
The National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatme...
AbstractIn the National Cancer Institute's Second International Workshop on the Biology, Prevention,...
Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantati...
AbstractIn the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment...
Prevention of relapse after allogeneic hematopoietic stem cell transplantation is the most likely ap...
The success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the infusion of ...
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for treatme...
Relapse has become the major cause of treatment failure after allogeneic hematopoietic stem cell tra...
Significant progress has been made over the past decade in haploidentical transplantation, with the ...
Disease relapse remains a major cause of mortality following allogeneic hematopoietic cell transplan...
AbstractOutcomes of hematopoietic cell transplantation continue to improve. New techniques have redu...